IL-6 Regulation of Energy Stores During Recovery From an Acute Exercise Bout (NCT05349149) | Clinical Trial Compass
CompletedNot Applicable
IL-6 Regulation of Energy Stores During Recovery From an Acute Exercise Bout
Denmark30 participantsStarted 2022-04-20
Plain-language summary
The aim of the study is to investigate the role of exercise-induced IL-6 in regulating energy stores and energy metabolism during recovery after an acute exercise bout. To achieve this, 30 men will be randomized to infusion placebo or tocilizumab (IL-6 receptor antibody) combined with a 2-hour exercise bout. Stable isotope tracers will be infused to determine substrate kinetics. Indirect calorimetry will be applied to determine substrate oxidation, and muscle biopsies will be taken to determine substrate uptake and storage.
Who can participate
Age range
18 Years – 40 Years
Sex
MALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Physically active (defined as meeting the ACSM's guidelines of 2.5h per week of moderate to vigorous physical activity per week), young, healthy males will be included. Participants may be included in the study if they meet all the following criteria:
* Age ≥ 18 years and ≤ 40 years
* BMI \< 18 and \> 25 kg/m2
* Healthy (based on screening)
* Stable body weight for 6 months
* ≥ 2.5h/week moderate to vigorous physical activity
Exclusion Criteria:
* • Cardiovascular disease
* Rheumatologic disease
* Metabolic disease
* Elite sports or high aerobic training status (VO2max \> 60 mL O2/min/kg)
* Frequent/chronic use of medications affecting physical performance or inflammation (NSAIDS, DMARDS, corticosteroids)
* Aspirin use \>100 mg/d
* Thyroid disease
* Current infection
* Aspartate amino transferase (AST) or alanine amino transferase (ALT) \>2x upper normal range
* History of carcinoma
* History of tuberculosis
* Ketogenic diet
* Smoking
* Anemia (hematocrit \<33%)
* Neutrophil count \<0,5x 109/l
* Thrombocytes \<50x 109/l or bleeding disorders
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in muscle glycogen content (mmol/kg/h)
Timeframe: Measured at 0, 120, 180 and 360 minutes
2
Change in muscle triglycerides content
Timeframe: Measured at 0, 120, 180 and 360 minutes
3
Change in muscle expression of glucose transporter type 4 (GLUT4)
Timeframe: Measured at 0, 120 and 360 min
4
Change in muscle expression of fatty acid translocase (FAT/CD36)
Timeframe: Measured at 0, 120 and 360 min
5
Change in muscle expression of muscle fatty acid binding protein (FABPm)
Timeframe: Measured at 0, 120 and 360 min
6
Change in muscle expression of fatty acid transporter 4 (FATP4)
Timeframe: Measured at 0, 120 and 360 min
7
Change in muscle expression of glycerol transporters